2 FTSE 100 growth giants that could fund your retirement

These two rising FTSE 100 (INDEXFTSE:UKX) stocks could help you to a comfortable old age.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you’re investing for your retirement, what should you do differently? I’d say nothing at all, because a good retirement investment strategy is simply a good investment strategy.Strategies aimed at maximising your long-term returns have a habit of turning out to be the most successful, whatever your age or plans.

To that end, there are many good stocks that should be good for long-term growth, and today I’m looking at two from the FTSE 100.

A new growth phase

AstraZeneca (LSE: AZN) has suffered a bit in recent years as the loss of patent protection on some key drugs has opened the way for cheap generic competition. Earnings have fallen as a result and the company has been working hard to focus on its core business and reinvigorate its development pipeline. 

You might imagine that the shares have had a few tough years as we await news of a return to earnings growth. But you’d be wrong, as AstraZeneca shares have actually gained 65% over the past five years, to 4,725p today. And over that period, the company has kept on paying dividends of around 5% and better.

So how will AstraZeneca do in a renewed period of sustainable growth? I think it will do very well indeed, and that were are on the verge of exactly that. Analysts seem to think the turnaround in earnings per share should happen in 2018 as the changes made by Pascal Soriot since he took the helm in 2012 are bearing fruit.

As of 2016 results time, 12 new drugs candidates had reached the Phase III stage or were under regulatory review, targeting oncology, cardiovascular and metabolic diseases and respiratory conditions, which are all growing first-world problems. And there are some clear candidates to become the blockbusters of tomorrow.

AstraZeneca shares are on a P/E of 15 on 2018 forecasts, and I reckon that could shrink rapidly over the next 10 years and make the shares look a real bargain today.

A hidden secret

GKN (LSE: GKN) is a company that has largely evaded me so far as its share price has somewhat stagnated in recent years, but while searching for solid growth candidates it has caught my eye. There was a minor dip in 2015, but since the end of 2012 the automotive engineer has grown its earnings per share by 18% — and forecasts suggest a gain of 37% by 2018.

Over the same period, dividends have been modest in the 2%-3% range, but they’re progressive and have been growing well ahead of inflation. That trend is expected to continue, and for me a dividend that is growing reliably in real terms is a very desirable thing.

Results for 2016 showed a 22% rise in revenue, which boosted adjusted pre-tax profit by 12%, and forecasts suggest two more years of earnings growth. And despite a one-off restructuring charge of £39m, the firm reckoned that has resulted in annualised savings of £30m.

We’re looking at a company here that has come through a restructuring phase, has what I see as attractive growth potential over the next decade and more, and whose shares are trading on a forward P/E of only around 10. That looks to me to be a great candidate for a retirement portfolio.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns shares of GKN. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Night Takeoff Of The American Space Shuttle
Investing Articles

Should I buy Nasdaq stock Micron for my ISA after blowout Q2 earnings?

Nasdaq tech stock Micron is generating incredible revenue growth at the moment amid the AI boom. Yet it still looks…

Read more »

Hand flipping wooden cubes for change wording" Panic" to " Calm".
Investing Articles

Is it time to dump my shares ahead of an almighty stock market crash? Nah!

How should we cope with growing fears of a stock market crash? 'Keep Calm and Carry On' worked in 1939,…

Read more »

Business man pointing at 'Sell' sign
Investing Articles

As the FTSE 100 tanks, consider buying this cheap dividend stock with a 7.3% yield

The FTSE 100 index is in meltdown mode due to the spike in oil prices. This is creating opportunities for…

Read more »

Sun setting over a traditional British neighbourhood.
Investing Articles

UK investors should consider buying shares in Uber. Here’s why

Uber shares could be a great fit for long-term UK investors that are looking to generate capital growth, says Edward…

Read more »

This way, That way, The other way - pointing in different directions
Growth Shares

£1k invested in Rolls-Royce shares at the beginning of the year is currently worth…

Jon Smith points out how well Rolls-Royce shares have done so far in 2026, but issues caution when looking further…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Value Shares

It might not feel like it, but this is the time to think about buying stocks

The FTSE 100 isn’t the first place most investors look for quality growth stocks to consider buying. But Stephen Wright…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

How are Lloyds shares looking in March 2026?

Lloyds shares have taken a tumble in the last month. What has happened? And could this be a golden opportunity…

Read more »

piggy bank, searching with binoculars
Investing Articles

Are Barclays shares really 50% cheaper than HSBC right now?

Barclays shares are trading at a price-to-book ratio half that of rivals like HSBC. Ken Hall looks at what the…

Read more »